HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Georges E Rivard Selected Research

Quebec platelet disorder

12/2020Thrombin generation abnormalities in Quebec platelet disorder.
12/2020Improved platelet counts during prolonged tranexamic therapy for Quebec platelet disorder implicate the underlying fibrinolytic defect as the cause of lower platelet counts.
1/2017The duplication mutation of Quebec platelet disorder dysregulates PLAU, but not C10orf55, selectively increasing production of normal PLAU transcripts by megakaryocytes but not granulocytes.
9/2011Quebec platelet disorder: update on pathogenesis, diagnosis, and treatment.
2/2010Persons with Quebec platelet disorder have a tandem duplication of PLAU, the urokinase plasminogen activator gene.
2/2009Quebec platelet disorder is linked to the urokinase plasminogen activator gene (PLAU) and increases expression of the linked allele in megakaryocytes.
2/2009Increased expression of urokinase plasminogen activator in Quebec platelet disorder is linked to megakaryocyte differentiation.
7/2008Evaluation of urokinase plasminogen activator in urine from individuals with Quebec platelet disorder.
7/2004Bleeding risks associated with inheritance of the Quebec platelet disorder.
8/2003Intracellular activation of the fibrinolytic cascade in the Quebec Platelet Disorder.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Georges E Rivard Research Topics

Disease

11Hemorrhage
07/2021 - 08/2003
10Quebec platelet disorder
12/2020 - 08/2003
3Hemophilia A (Haemophilia)
06/2018 - 11/2005
2Angioedema
08/2020 - 01/2020
2Hereditary Angioedemas
08/2020 - 01/2020
1Synovitis
10/2021
1Fibrinolytic Defect
12/2020
1Acquired angioedema
01/2020
1Edema (Dropsy)
01/2020
1Infections
06/2018
1Joint Diseases (Joint Disease)
06/2018
1Metrorrhagia (Spotting)
06/2018
1Leukemia
01/2011
1Leukemia L1210
01/2011
1Hemophilia B (Haemophilia B)
11/2005
1Hypotension (Low Blood Pressure)
10/2005
1Amniotic Fluid Embolism
10/2005
1Type 1 von Willebrand Disease
07/2003

Drug/Important Bio-Agent (IBA)

10Urokinase-Type Plasminogen Activator (Urokinase)FDA Link
12/2020 - 08/2003
8Plasminogen Activators (Plasminogen Activator)IBA
12/2020 - 03/2008
3Factor VIII (Coagulation Factor VIII)IBA
07/2021 - 03/2009
3BradykininIBA
08/2020 - 10/2005
2ThrombinFDA Link
12/2020 - 11/2005
2Proteins (Proteins, Gene)FDA Link
12/2020 - 08/2003
2FibrinolysinFDA Link
12/2020 - 02/2009
2Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA
08/2020 - 01/2020
2Hemostatics (Antihemorrhagics)IBA
03/2008 - 07/2004
1HemosiderinIBA
10/2021
1Blood Group Antigens (Blood Groups)IBA
07/2021
1Factor V (Coagulation Factor V)IBA
12/2020
1lipoprotein-associated coagulation inhibitor (TFPI)IBA
12/2020
1icatibantIBA
08/2020
1LigandsIBA
08/2020
1CollagenIBA
07/2020
1ORALIT (ORS)IBA
07/2020
1Factor XII (Hageman Factor)IBA
01/2020
1PlasminogenIBA
01/2020
1Blood Coagulation Factors (Coagulation Factor)IBA
06/2018
1Pharmaceutical PreparationsIBA
01/2011
1Cytarabine (Cytosar-U)FDA LinkGeneric
01/2011
1AntibodiesIBA
03/2009
1EnzymesIBA
03/2008
1AminoglycosidesIBA
11/2005
1AntigensIBA
11/2005
1Nonsense Codon (Nonsense Mutation)IBA
11/2005
1Gentamicins (Gentamicin)FDA LinkGeneric
11/2005
1Factor IX (Coagulation Factor IX)FDA LinkGeneric
11/2005
1von Willebrand FactorIBA
07/2003

Therapy/Procedure

2Therapeutics
12/2020 - 03/2008
1Central Venous Catheters
06/2018
1HAD protocol
06/2018